PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
23.04%
R&D growth while AGEN reduces spending. John Neff would investigate strategic advantage.
21.61%
G&A growth while AGEN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.65%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
22.65%
Total costs growth while AGEN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
3.49%
D&A growth 1.25-1.5x AGEN's 2.35%. Martin Whitman would scrutinize asset base.
-23.08%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-22.65%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-58.12%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-23.20%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.20%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-16.67%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-22.50%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
5.52%
Share count reduction below 50% of AGEN's 3.44%. Michael Burry would check for concerns.
0.56%
Diluted share reduction exceeding 1.5x AGEN's 3.44%. David Dodd would verify capital allocation.